Adherence and drug resistance: Predictions for therapy outcome

Proceedings of the Royal Society B: Biological Sciences

Volumn 267, Issue 1445, 2000, Pages 835-843

  Wahl, Lindi M ^a   Nowak, Martin A ^a  

^a INSTITUTE FOR ADVANCED STUDY   (United States)

Author keywords

Adherence; HIV; Immunology; Pharmacokinetics; Resistance; Virology

Indexed keywords

LAMIVUDINE; RITONAVIR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT COMPLIANCE; PHARMACOKINETICS; PREDICTION; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS REPLICATION; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0034701490     PISSN: 09628452     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rspb.2000.1079     Document Type: Article

References (44)

1. Anderson, R. M. & May, R. M. 1991 Infectious diseases of humans: dynamics and control. Oxford University Press.
2. Austin, D. J. & Anderson, R. M. 1999 Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models. Phil. Trans. R. Soc. Lond. B 354, 721-738.
3. Austin, D. J., Kakehashi, M. & Anderson, R M. 1997 The transmission dynamics of antibiotic-resistant bacteria: the relationship between resistance in commensal organisms and antibiotic consumption. Proc. R. Soc. Lond. B 264, 1629-1638.
4. Austin, D. J., White, N. J. & Anderson, R. M. 1998 The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. J. Theor. Biol. 194, 313-339.
5. Austin, D. J., Kristinsson, K. G. & Anderson, R. M. 1999 The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc. Natl Acad. Sci. USA 96, 1152-1156.
6. Besch, C. L. 1995 Compliance in clinical trials. AIDS 9, 1-10.
7. Bonhoeffer, S. & Nowak, M. A. 1997 Pre-existence and emergence of drug resistance in HIV-1 infection. Proc. R. Soc. Lond. B 264, 631-637.
8. Bonhoeffer, S., Lipsitch, M. & Levin, B. R. 1997a Evaluating treatment protocols to prevent antibiotic resistance. Proc. Natl Acad. Sci. USA 94, 12106-12111.
9. Bonhoeffer, S., May, R. M., Shaw, G. M. & Nowak, M. A. 1997b Virus dynamics and drug therapy. Proc. Natl Acad. Sci. USA 94, 6971-6976.
10. Coffin, J. M. 1995 HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 267, 483-489.
11. Davies, J. E. 1997 Origins, acquisition and dissemination of antibiotic resistance determinants. Ciba Found. Symp. 207, 15-27.
12. de Jong, M. D., Veenstra, J., Stilianakis, N. I., Schuurman, R., Lange, J. M., de Boer, R. J. & Boucher, C. A. 1996 Hostparasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. Proc. Natl Acad. Sci. USA 93, 5501-5506.
13. Dietz,, K. 1975 Transmission and control of arbovirus diseases. In Epidemiology (ed. D. Ludwig & K. L. Cooke) pp. 104-121. Philadelphia, PA: SIAM.
14. Dietz, K. 1976 The incidence of infectious diseases under the influence of seasonal fluctuations. Lect. Notes Biomath. 11, 1-15.
15. Frost, S. D. W. & McLean, A. R. 1994 Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection. AIDS 8, 323-332.
16. Hoetelmans, R. M., Meenhorst, P. L., Mulder, J.W., Burger, D. M., Koks, C. H. & Beijnen, J. H. 1997 Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharmacol. World Sci. 19, 159-175.
17. Ickovics, J. R. & Meisler, A. W. 1997 Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J Clin. Epidemiol. 50, 385-391.
18. Jarvis, B. & Faulds, D. 1998 Nelfinavir. A review of its therapeutic efficacy in HIV infection. Drugs 56, 147-167.
19. Katzenstein, D. A. 1997 Adherence as a particular issue with protease inhibitors. J. Assoc. Nurses AIDS Care 8(Suppl.), 10-17.
20. Kepler, T. B. & Perelson, A. S. 1998 Drug concentration heterogeneity facilitates the evolution of drug resistance. Proc. Natl Acad. Sci USA 95, 11514-11519.
21. Lea, A. P. & Faulds, D. 1996 Ritonavir. Drugs 52, 541-546.
22. Levin, S. A. & Andreason, V 1999 Disease transmission dynamics and the evolution of antibiotic resistance in hospitals and communal settings. Proc. Natl Acad. Sci. USA 96, 800-801.
23. Levin, B. R., Lipsitch, M., Perrot, V., Schrag, S., Antia, R., Simonsen, L., Walker, N. M. & Stewart, F. M. 1997 The population genetics of antibiotic resistance. Clin. Infect. Dis. 24(Suppl. 1), S9-S16.
24. Levin, B. R. (and 19 others) 1998 Resistance to antimicrobial chemotherapy: a prescription for research and action. Am. J. Med. Sci. 315, 87-94.
25. Levin, S. A., Lipsitch, M. & Bonhoeffer, S. 1999 Population biology, evolution, and infectious disease: convergence and synthesis. Science 283, 806-809.
26. Levy, S. B. 1997 Antibiotic resistance: an ecological imbalance. Ciba Found. Symp. 207, 1-9.
27. Lipsitch, M. & Levin, B. R. 1997 The population dynamics of antimicrobial chemotherapy. Antimicrob. Agents Chemother. 41, 363-373.
28. Lipsitch, M. & Levin, B. R. 1998 The population dynamics of tuberculosis chemotherapy: mathematical models of the roles of noncompliance and bacterial heterogeneity in the evolution of drug resistance. Int. J. Tuberculosis Lung Dis. 2, 187-199.
29. Macdonald, G. 1952 The analysis of equilibrium in malaria. Trop. Dis. Bull. 49, 813-829.
30. McDonald, C. K. & Kuritzkes, D. R. 1997 Human immunodeficiency virus type 1 protease inhibitors. Arch. Intern. Med. 157, 951-959.
31. McLean, A. R. & Nowak, M. A. 1992 Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV, AIDS 6, 71-79.
32. May, R. M. & Anderson, R. M. 1979 Population biology of infectious diseases II. Nature 280, 455.
33. Mayers, D. 1996 Rational approaches to resistance: nucleoside analogues. AIDS 10(Suppl. 1), S9-S13.
34. Mehta, S., Moore, R. D. & Graham, N. M. 1997 Potential factors affecting adherence with HIV therapy. AIDS 11, 1665-1670.
35. Moyle, G. & Gazzard, B. 1996 Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 51, 701-712.
36. Nowak, M. A., Anderson, R. M., McLean, A. R., Wolfs,T. F. W., Goudsmit, J. & May, R. M. 1991 Antigenic diversity thresholds and the development of AIDS. Science 254, 963-969.
37. Nowak, M. A., Bonhoeffer, S., Shaw, G. M. & May, R. M. 1997 Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J. Theor. Biol. 184, 203-217.
38. Paterson, D., Swindells, S., Mohr, J., Brester, M., Yergis, E., Squier, C., Wagener, M. & Singh, N. 1999 How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMSCaps. In Proceedings of the Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, Abstract 092.
39. Ribeiro, R. M., Bonhoeffer, S. & Nowak, M. A. 1998 The frequency of resistant mutant virus before anti-viral therapy. AIDS 12, 461-465.
40. Richman, D. D., Meng, T. C., Spector, S. A., Fischl, M. A., Resnick, L. & Lai, S. 1994 Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus. J. AIDS 7, 135-138.
41. Schuurman, R. (and 12 others) 1995 Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171, 1411-1419.
42. Stilianakis, N. I., Boucher, C. A., de Jong, M. D., Van Leeuwen, R., Schuurman, R. & de Boer, R. J. 1997 Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model. J. Virol. 71, 161-168.
43. United States Department of Health and Human Services 1999 Adherence to potent antiretroviral therapy. In Guidelines on the optimal use of antiretroviral therapies in HIV infected adults and adolescents. Available at http://www.aids. wustl.edu/aids/clinguide.html.
44. Yorke, J. A., Nathanson, N., Pianingiani, G. & Martin, J. 1979 Seasonality and the requirements for perpetuation and eradication of viruses. Am. J. Epidemiol. 109, 103-123.